BACKGROUND: The European Organization for Research and Treatment of Cancer (EORTC) 24954 phase 3 randomized clinical trial compared 2 schemes of combined chemotherapy for patients with resectable cancers of the hypopharynx and larynx: sequential induction chemotherapy and radiotherapy versus alternating chemoradiotherapy. The current study reports detailed effects of both treatment arms on health-related quality of life (HRQOL) and symptoms. METHODS: A total of 450 patients aged 35 years to 76 years (World Health Organization performance status (WHO PS) ≤ 2) with untreated, resectable advanced squamous cell carcinoma of the larynx (tumor classification of T3-T4) or hypopharynx (tumor classification of T2-T3-T4) with regional lymph nodes in the neck classified as N0 to N2 with no metastases were randomized in this prospective phase 3 trial into either the sequential arm (control) or the alternating arm (experimental). QOL assessment was performed at randomization; at baseline; at 42 days; and at 6, 12, 24, 36, and 48 months. RESULTS: There were no observed differences with regard to the primary endpoint of Fatigue and secondary endpoint of Dyspnea. Significant differences were found in the secondary endpoints of Swallowing and Speech problems at 42 days after randomization in favor of patients in the sequential arm. Explanatory and sensitivity analysis revealed that the primary analysis favored the sequential arm, but the majority of differences in HRQOL did not exist at the end of treatment, and returned to baseline levels. CONCLUSIONS: In the current study, a trend toward worse scores was noted in the patients treated on the alternating chemoradiotherapy arm but very few differences reached the level of statistical significance. The HRQOL scores of the majority of patients returned to baseline after therapy.
RCT Entities:
BACKGROUND: The European Organization for Research and Treatment of Cancer (EORTC) 24954 phase 3 randomized clinical trial compared 2 schemes of combined chemotherapy for patients with resectable cancers of the hypopharynx and larynx: sequential induction chemotherapy and radiotherapy versus alternating chemoradiotherapy. The current study reports detailed effects of both treatment arms on health-related quality of life (HRQOL) and symptoms. METHODS: A total of 450 patients aged 35 years to 76 years (World Health Organization performance status (WHO PS) ≤ 2) with untreated, resectable advanced squamous cell carcinoma of the larynx (tumor classification of T3-T4) or hypopharynx (tumor classification of T2-T3-T4) with regional lymph nodes in the neck classified as N0 to N2 with no metastases were randomized in this prospective phase 3 trial into either the sequential arm (control) or the alternating arm (experimental). QOL assessment was performed at randomization; at baseline; at 42 days; and at 6, 12, 24, 36, and 48 months. RESULTS: There were no observed differences with regard to the primary endpoint of Fatigue and secondary endpoint of Dyspnea. Significant differences were found in the secondary endpoints of Swallowing and Speech problems at 42 days after randomization in favor of patients in the sequential arm. Explanatory and sensitivity analysis revealed that the primary analysis favored the sequential arm, but the majority of differences in HRQOL did not exist at the end of treatment, and returned to baseline levels. CONCLUSIONS: In the current study, a trend toward worse scores was noted in the patients treated on the alternating chemoradiotherapy arm but very few differences reached the level of statistical significance. The HRQOL scores of the majority of patients returned to baseline after therapy.
Keywords:
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30); alternating chemoradiotherapy; chemotherapy; health-related quality of life; hypopharynx cancer; larynx cancer; radiotherapy
Authors: Jeffrey M Vainshtein; Dominic H Moon; Felix Y Feng; Douglas B Chepeha; Avraham Eisbruch; Matthew H Stenmark Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-01 Impact factor: 7.038
Authors: Elise M Gane; Steven M McPhail; Anna L Hatton; Benedict J Panizza; Shaun P O'Leary Journal: Eur Arch Otorhinolaryngol Date: 2017-09-22 Impact factor: 2.503
Authors: Eleni M Rettig; Gypsyamber D'Souza; Carol B Thompson; Wayne M Koch; David W Eisele; Carole Fakhry Journal: Cancer Date: 2016-05-16 Impact factor: 6.860
Authors: Birsen Yucel; Ebru Atasever Akkaş; Yillar Okur; Ayfer Ay Eren; Mehmet Fuat Eren; Hanife Karapinar; Nalan Akgül Babacan; Saadettin Kiliçkap Journal: Support Care Cancer Date: 2014-04-12 Impact factor: 3.603
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Rhys Weaver; Moira O'Connor; Raelee M Golding; Chandrika Gibson; Rohen White; Melanie Jackson; Danette Langbecker; Anna Maria Bosco; Maureen Tan; Georgia K B Halkett Journal: Support Care Cancer Date: 2022-01-23 Impact factor: 3.359
Authors: B J Heijnen; R Speyer; B Kertscher; R Cordier; K W J Koetsenruijter; K Swan; H Bogaardt Journal: Biomed Res Int Date: 2016-09-19 Impact factor: 3.411
Authors: Chantal M L Driessen; Johannes M M Groenewoud; Jan Paul de Boer; Hans Gelderblom; Winette T A van der Graaf; Judith B Prins; Johannes H A M Kaanders; Carla M L van Herpen Journal: Support Care Cancer Date: 2017-12-11 Impact factor: 3.603